RGPXdelisted

REGENEREX PHARMA, INC.

Healthcare·Dermatology·Commercial
Dermatology

REGENEREX PHARMA, INC. (RGPX): 8 pipeline candidates · ~0 mo cash runway. Updated within the last hour.

7.5/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.0

0.1 months

Financial Health10.0

D/E -1.13 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

8 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for REGENEREX PHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$12K

Quarterly Burn

$519K

Runway

0.1 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jun 2026
Today~7 mo out
Catalyst within runway

Pipeline (8 candidates)

Frequently asked questions

How many drug candidates are in REGENEREX PHARMA, INC.'s pipeline?

REGENEREX PHARMA, INC. (RGPX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is REGENEREX PHARMA, INC.'s lead drug candidate?

REGENEREX PHARMA, INC.'s most advanced tracked candidate is accelerex impregnated sterile wound dressing (Approved) for pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

What is REGENEREX PHARMA, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, REGENEREX PHARMA, INC. has approximately 0.1 months of cash runway.

Get the full picture on REGENEREX PHARMA, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.